Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up to $7.70

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) gapped up before the market opened on Wednesday . The stock had previously closed at $7.70, but opened at $8.15. Recursion Pharmaceuticals shares last traded at $8.17, with a volume of 2,353,803 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RXRX. Needham & Company LLC restated a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. TD Cowen assumed coverage on shares of Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating for the company. Finally, KeyCorp upped their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $12.75.

Recursion Pharmaceuticals Trading Up 4.7 %

The stock’s fifty day moving average is $10.62 and its two-hundred day moving average is $9.12. The company has a market capitalization of $1.89 billion, a PE ratio of -5.14 and a beta of 0.76.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The firm had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, COO Tina Marriott Larson sold 8,000 shares of the firm’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $10.35, for a total value of $82,800.00. Following the completion of the sale, the chief operating officer now owns 414,548 shares of the company’s stock, valued at $4,290,571.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $12.32, for a total value of $247,065.28. Following the completion of the sale, the director now directly owns 7,292,863 shares in the company, valued at approximately $89,848,072.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Tina Marriott Larson sold 8,000 shares of the firm’s stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $10.35, for a total value of $82,800.00. Following the completion of the transaction, the chief operating officer now directly owns 414,548 shares in the company, valued at $4,290,571.80. The disclosure for this sale can be found here. Insiders have sold 356,218 shares of company stock worth $3,619,264 over the last ninety days. Insiders own 19.96% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. National Bank of Canada FI increased its position in Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after buying an additional 1,500 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Recursion Pharmaceuticals by 6.2% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 33,002 shares of the company’s stock worth $252,000 after buying an additional 1,938 shares during the last quarter. Wedmont Private Capital boosted its stake in Recursion Pharmaceuticals by 11.8% during the first quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after buying an additional 2,000 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Recursion Pharmaceuticals by 25.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after buying an additional 2,050 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Recursion Pharmaceuticals by 116.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock valued at $40,000 after purchasing an additional 2,817 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.